Haemophilia B MedDRA version: 12.1 Level: LLT Classification code 10018939 Term: Haemophilia B (Factor IX)
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Previous participation in NN7999-3747 and/or NN7999-3773 Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: • Known history of FIX inhibitors based on existing medical records, laboratory report reviews and patient and LAR interviews • Current FIX inhibitors =0.6 BU • Congenital or acquired coagulation disorders other than haemophilia B • Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records) • Any disease (liver, kidney, inflammatory and mental disorders included) or condition which, according to the Investigator’s judgement, could imply a potential hazard to the patient, interfere with trial participation, or interfere with trial outcome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: • To evaluate clinical efficacy of haemostasis (treatment of bleeding episodes) of NNC-0156-0000-0009 • To evaluate clinical efficacy of NNC-0156-0000-0009 in long term bleeding prophylaxis (number of bleeding episodes during prophylaxis) • To evaluate efficacy of NNC-0156-0000-0009 by the surrogate marker for efficacy, FIX activity • To evaluate general safety of NNC-0156-0000-0009;Main Objective: To evaluate the immunogenicity of NNC-0156-0000-0009.;Primary end point(s): Incidence of inhibitory antibodies against FIX defined as titre =0.6 BU | — |
Countries
Austria, France, Germany, Greece, Italy, Netherlands, Spain, United Kingdom